Endocyte Inc.
Endocyte Announces Positive Results from a Phase II Clinical Study of EC145 in Patients with Advanced Non-Small Cell Lung Cancer NSCLC
Published in Drug Law Weekly, August 25th, 2009
Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.
"The data...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-08-25)
More Articles from Drug Law Weekly
- Astellas Pharma US, Inc.
Update on Astellas' Request for Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications - Breast Cancer
Recent studies from University of California, Medical Department add new data to psychiatry - Bureau of Alcohol, Tobacco, Firearms and Explosives
ATF, U.S. Attorney, Arizona Attorney General and Firearms Industry Join Forces to Stop Illegal Purchases of Firearms in Tucson - Defibrillators
Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches - Generics
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) - HIV/AIDS
Federal Judge Sentences Defendants Who Perpetrated $10.9 Million Medicare Fraud HIV Infusion Scheme - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
